Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo Controlled, Double Blind, Randomised, 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia

NCT00776321 is registered in ClinicalTrials.gov with Karo Bio AB as lead sponsor.

NCT NCT00776321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00776321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo Controlled, Double Blind, Randomised, 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia
Lead sponsor
Karo Bio AB
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2006
Completion date
October 31, 2007
Enrollment
142 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary hypercholesterolemia